1. Clinical-Risk Factors that Influence an Optimal Hypomethylating Agents Treatment in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. (April 2017) Authors: Iastrebner, M.; Lazzarino, C.; Nucifora, E.; Penchasky, D.; Fernandez, I.; Gusmao Moreno, B.G.M.; Rivas, M.M.; Espinosa, D.; Abello Polo, V.; Boada, M.; Enrico, A.; Araujo Schuster, S.; Agra, M.; Sarmiento, M.; Flores, G.; Alfonso, G.; Crisp, R.; Gusmao Moreno, B.; Consortium, I. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. False‐positive lupus anticoagulant results by DRVVT in the presence of rivaroxaban even at low plasma concentrations. (29th May 2018) Authors: Martinuzzo, M. E.; Forastiero, R.; Duboscq, C.; Barrera, L. H.; López, M. S.; Ceresetto, J.; Penchasky, D.; Oyhamburu, J. Journal: International journal of laboratory hematology Issue: Volume 40:Number 5(2018:Oct.) Page Start: e99 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗